ASC Industry News

Check out these articles for some of the latest hot topics in ASC Industry News:

10 Key Trends for ASCs and Outpatient Surgery in the Next 10 Years

Here are 10 predictions and key trends for outpatient surgery and ASCs, including key specialties and outpatient growth, through 2027. 1) Over the next decade, inpatient discharges are expected to decrease 2 percent while outpatient volumes will likely grow 15 percent across the U.S., according to Sg2 predictions…

Source: Becker’s ASC


HOPD to ASC Conversion: Now or Later

Regent Surgical Health, one of the largest private joint venture operators of surgery centers in the United States, released a white paper today which defines a trend that empowers health systems to adapt and thrive in a landscape punctuated by advances in technology, shifting public policy, and an industry-wide move toward value-based care. The paper, “HOPD to ASC Conversion: Now or Later with Transition to Value-Based Care,” examines how market conditions have influenced the reversal of a trend that, only a few years ago, saw hospitals buying ambulatory surgery centers (ASCs) outright and converting them to hospital outpatient departments (HOPDs).

Source: ASCA/Regent Surgical Health


You Can’t Put a Price on Pupillary Dilation

Working through small pupils during cataract surgery must be as frustrating as trying to squeeze a profit out of what Medicare pays your facility to host the case. Reimbursements certainly aren’t going to increase anytime soon and inadequate intraoperative mydriasis is becoming an increasingly common problem, so team up with your surgeons to find a cost-effective way to dilate pupils and dial up revenues.

Source: Outpatient Surgery


FDA Warns Duodenoscope Manufacturers About Failure to Comply with Required Postmarket Surveillance Studies to Assess Contamination Risk

The U.S. Food and Drug Administration today issued warning letters to all three duodenoscope manufacturers for failing to comply with requirements of federal law under which they were ordered to conduct postmarket surveillance studies to assess the effectiveness of reprocessing the devices. As part of an ongoing effort to prevent patient infections associated with the transmission of bacteria from contaminated duodenoscopes, the FDA in 2015 ordered U.S. duodenoscope manufacturers Olympus, Fujifilm and Pentax to conduct a postmarket surveillance study to determine whether healthcare facilities were able to properly clean and disinfect the devices.

Source: ASCA/FDA

0 replies

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *